Within a framework of the state measles elimination program, in April, 2018 a level of measles herd immunity was assessed in 1899 Moscow hospital medical workers aged from 19 to 69 years and older. All subjects enrolled in the study were vaccinated against measles or recovered after measles infection. Serum samples were collected from subjects and examined by ELISA for measles IgG antibodies with the Vector-Best IgG-measle test system (Russia). It was found that 278 (14.6%) and 1621 (85.4%) subjects were seronegative ( 0.18 IU/mL) and seropositive ( 0.18 IU/ml), respectively. Age-related group distribution of 1855 serum samples revealed that percentage of seronegative subjects was in: aged 19—23 years was -38.5%; 24-28 and 29-33 years - 22.2%; 34-38 years - 27.5%; 39-43 years - 25.8%; 44-48 years - 16.8%; 49-53 and 54-58 years — 8.6% and 8.3%, respectively; 59-63 years old — 4.9%; 64-68 and over 69 years old — 0%. Moreover, mean level of measles IgG antibodies increased proportionally to age of medical workers from 0.58 IU/ml (19-23 years) to 2.94-2.72 IU/ml (64-68 and over 69 years). The data obtained indicate that a cohort of measles susceptible subjects (from 38.5% to 16.8%), respectively, is identified among young and middle age (from 19 to 48 years) individuals. It is assumed that two-dose measles vaccination in childhood does not contribute to the long-term preservation of protective levels of measles antibodies, thereby justifying a need to administer a three-dose measles vaccine.

Background: SARS-CoV-2 infection has raised concerns about altered immune responses, creating a need to evaluate influenza vaccine performance in the post-COVID period. This study aimed to compare the immunogenicity and safety of a quadrivalent inactivated subunit adjuvanted influenza vaccine in adults aged 18–85 years during the 2022–2023 season. Methods: A total of 144 adults were enrolled: group 1, aged 18–59 years (n = 124), and group 2, aged 60–85 years (n = 20). All received a quadrivalent inactivated subunit adjuvanted vaccine containing 5 μg of each influenza antigen and 500 μg of Azoximer bromide. IgG antibodies to vaccine strains were measured at baseline and days 30–32 using the hemagglutination inhibition assay. Participants were actively monitored for adverse events by telephone. Results: The Geometric Mean Fold Increase (GMFI) met the efficacy criteria in both age groups (≥2.5 for 18–59 years and ≥2.0 for 60–85 years), with no significant differences. The seroprotection rate reached accepted thresholds for most strains but was below criteria for B/Victoria in the 18–59 group (48%) and for B/Phuket in the 60–85 group (35%). Significant between-group differences were observed for B/Victoria (p = 0.01) and B/Phuket (p = 0.007). Seroconversion met criteria for all strains in younger adults, but for older adults, it was insufficient for B/Phuket (20%, below the ≥30% threshold; p = 0.05 vs. 18–59 years). Local reactions occurred in 24.2% and systemic in 11.3% of younger adults; in older adults, in 20% and 15%, respectively. All resolved spontaneously within 1–3 days. Conclusions: The quadrivalent adjuvanted influenza vaccine demonstrated acceptable immunogenicity and safety in adults aged 18–85 years despite potential post-COVID immune alterations.

Background: Influenza vaccine is a tool for preventing infection and reducing exacerbations in patients with asthma and chronic obstructive pulmonary disease (COPD). Purpose of this study is to investigate dynamics of CRP and serum cytokines (IL-2, IL-6, IL-10, IL-17) in patients with asthma and COPD, as well as to perform a correlation analysis with the clinical parameters of the disease manifestation. Methods: The study included 34 patients with asthma, 20 patients with COPD vaccinated against influenza during a period of remission from 2 to 4 weeks, both groups being under a basic maintenance therapy, and 26 healthy individuals vaccinated with the trivalent polymer-subunit vaccine Grippol® Plus, containing 5 µg of influenza virus strains and 500 µg of azoximer bromide. Results: Observing patients with asthma and COPD, during a year after the vaccination, has revealed a significant reduction in exacerbations frequency (p < 0.05) and duration (p < 0.05) of the bronchial obstructive syndrome (BF). Before the vaccination the IL-6 level in patients with asthma had a direct moderate correlation with duration of exacerbations of the underlying disease (p < 0.05), along with the number of systemic corticosteroids courses during exacerbations (p < 0.05). In 12 months after the vaccination, while assessing cytokine profile of all study groups, a significant reduction in the level of IL-6 was observed, compared to the baseline values (p< 0.05). Conclusion: Conducted analysis of immunological, clinical, and functional parameters of patients with asthma and COPD has proven for influenza vaccine to be effective in BF patients.